臨床検査55巻11号

2011年10月発行

特集 ここまでわかった自己免疫疾患 各論 7．生物学的製剤の利点と欠点

生物学的製剤の利点と欠点

著者： 長坂憲治¹ 針谷正祥²³

所属機関： ¹青梅市立総合病院リウマチ・膠原病科 ²東京医科歯科大学大学院医歯学総合研究科薬害監視学講座 ³膠原病・リウマチ内科学

ページ範囲：P.1349 - P.1358

生物学的製剤とは，生物が産生する蛋白質を利用した製剤である．生物学的製剤は標的分子に高親和性を有し，病態にかかわる分子の機能を制御する結果，関節リウマチ(RA)をはじめとする多くの自己免疫疾患に有効であることが明らかとなった．生物学的製剤は，有効性が高い，複数の疾患に対して有効，臓器毒性が低い，といった利点がある．一方，経口投与ができない，コストが高い，抗製剤抗体産生による効果減弱，特異な副作用などの欠点がある．本邦ではRA治療薬として，TNF(tumor necrosis factor)阻害薬(インフリキシマブ，エタネルセプト，アダリムマブ)，IL-6(interleukin-6)阻害薬(トシリズマブ)，T細胞抑制薬(アバタセプト)が用いられており，関節炎の軽減と骨破壊抑制に優れた効果を発揮している．

参考文献

1) 亀田秀人，竹内勤：生物学的製剤の薬理作用．ファーマナビゲーター　リウマチ～生物学的製剤編～(竹内勤編)，メディカルレビュー社，pp22-33，2010

2) Calabrese LH : Molecular differences in anticytokine therapies. Clin Exp Rheumatol　21：241-248，2003

3) Mitoma H, Horiuchi T, Tsukamoto H, et al : Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells : comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum　58：1248-1257，2008

4) Ohshima S, Mima T, Sasai M, et al : Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells : a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. Cytokine　12：281-288，2000

5) ten Hove T, van Montfrans C, Peppelenbosch MP, et al : Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut　50：206-211，2002

6) Maini RN, Breedveld FC, Kalden JR, et al : Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum　41：1552-1563，1998

7) Lipsky PE, van der Heijde DM, St Clair EW, et al : Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med　343：1594-1602，2000

8) St Clair EW, van der Heijde DM, Smolen JS, et al : Combination of infliximab and methotrexate therapy for early rheumatoid arthritis : a randomized, controlled trial. Arthritis Rheum　50：3432-3443，2004

9) Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al : Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission : exploratory analyses from the BeSt study. Ann Rheum Dis　70：315-319，2011

10) Tanaka Y, Takeuchi T, Mimori T, et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis　69：1286-1291，2010

11) Okuyama A, Nagasawa H, Suzuki K, et al : Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis　70：299-304，2011

12) Klareskog L, van der Heijde D, de Jager JP, et al : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet　363：675-681，2004

13) Genovese MC, Bathon JM, Martin RW, et al : Etanercept versus methotrexate in patients with early rheumatoid arthritis : two-year radiographic and clinical outcomes. Arthritis Rheum　46：1443-1450，2002

14) Kameda H, Ueki Y, Saito K, et al : Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy : a randomized trial. Mod Rheumatol　20：531-538，2010

15) van de Putte LB, Atkins C, Malaise M, et al : Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis　63：508-516，2004

16) Keystone EC, Kavanaugh AF, Sharp JT, et al : Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy : a randomized, placebo-controlled, 52-week trial. Arthritis Rheum　50：1400-1411，2004

17) Breedveld FC, Weisman MH, Kavanaugh AF, et al : The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum　54：26-37，2006

18) Miyasaka N : Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation : the CHANGE study. Mod Rheumatol　18：252-262，2008

19) Nishimoto N, Miyasaka N, Yamamoto K, et al : Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol　19：12-19，2009

20) Nishimoto N, Hashimoto J, Miyasaka N, et al : Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis　66：1162-1167，2007

21) Emery P, Keystone E, Tony HP, et al : IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis　67：1516-1523，2008

22) Kremer JM, Genant HK, Moreland LW, et al : Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : a randomized trial. Ann Intern Med　144：865-876，2006

23) Genovese MC, Becker JC, Schiff M, et al : Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med　353：1114-1123，2005

24) Maxwell L, Singh JA : Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev　7：CD007277，2009

25) Ohno S, Nakamura S, Hori S, et al : Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol　31：1362-1368，2004